[{"id":"6ca41b4e-a9cf-4608-934c-6df02748d3e9","acronym":"ASLIC","url":"https://clinicaltrials.gov/study/NCT03156933","created_at":"2021-01-18T15:33:52.106Z","updated_at":"2024-07-02T16:37:22.112Z","phase":"","brief_title":"Alternative Splicing and Leukemia Initiating Cells","source_id_and_acronym":"NCT03156933 - ASLIC","lead_sponsor":"Hospices Civils de Lyon","biomarkers":" KRAS • FLT3 • KIT • NPM1 • RAS • ABCA3","pipe":" | ","alterations":" KRAS mutation","tags":["KRAS • FLT3 • KIT • NPM1 • RAS • ABCA3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation"],"overall_status":"Unknown status","enrollment":" Enrollment 500","initiation":"Initiation: 04/01/2017","start_date":" 04/01/2017","primary_txt":" Primary completion: 03/01/2018","primary_completion_date":" 03/01/2018","study_txt":" Completion: 04/01/2018","study_completion_date":" 04/01/2018","last_update_posted":"2017-05-17"}]